Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.
Rettie
A E
AE
Department of Medicinal Chemistry, University of Washington, Seattle 98195.
Wienkers
L C
LC
Gonzalez
F J
FJ
Trager
W F
WF
Korzekwa
K R
KR
D000483:Alleles; D001189:Aryl Hydrocarbon Hydroxylases; D065729:Cytochrome P-450 CYP2C9; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D011994:Recombinant Proteins / Q000378:metabolism; D013237:Stereoisomerism; D039181:Steroid 16-alpha-Hydroxylase; D014044:Tolbutamide / Q000031:analogs & derivatives / Q000032:analysis / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014859:Warfarin / Q000031:analogs & derivatives / Q000032:analysis / Q000378:metabolism*; D000096926:Benzenesulfonamides
D001189:Aryl Hydrocarbon Hydroxylases; D065729:Cytochrome P-450 CYP2C9; D003577:Cytochrome P-450 Enzyme System; D011994:Recombinant Proteins; D039181:Steroid 16-alpha-Hydroxylase; D014044:Tolbutamide; D014859:Warfarin; C031014:hydroxymethyltolbutamide; D000096926:Benzenesulfonamides; C087837:7-hydroxywarfarin; C450260:CYP2C9 protein, human; C008091:6-hydroxywarfarin